Core Viewpoint - The company, Xiehe New Energy, has received a notification from the China Securities Regulatory Commission regarding its application for a secondary listing on the Singapore Exchange, scheduled for December 12, 2025 [1] Group 1 - The company is planning to submit a listing application for a secondary listing on the Singapore Exchange [1] - The notification received from the China Securities Regulatory Commission pertains to the overseas issuance and listing record-keeping [1]

智通财经APP讯，协合新能源(00182)公布，就有关向新交所就建议第二上市提交上市申请，于2025年12 月12日，公司接获中国证券监督管理委员会就建议第二上市发出的境外发行上市备案通知书。 ...

Core Viewpoint - The company, Xiehe New Energy, has received a notification from the China Securities Regulatory Commission regarding its proposed secondary listing, indicating progress in its international expansion strategy [1] Group 1 - The company announced that it received a notification from the China Securities Regulatory Commission on December 12, 2025, regarding its proposed secondary listing [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明不會就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 Concord New Energy Group Limited 協 合 新 能 源 集 團 有 限 公 司 * （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代碼：182） 內幕消息 有關建議於新加坡證券交易所第二上市之更新 本公告乃由Concord New Energy Group Limited（協合新能源集團有限公司*）（「本公司」，連 同其附屬公司，統稱「本集團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則第 13.09(2)(a)條以及證券及期貨條例（香港法例第571章）第XIVA部而作出。 茲提述本公司於聯交所刊發日期為二零二五年二月二十七日，內容有關建議於新交所第二上 市之公告，以及本公司日期為二零二五年四月十六日，內容有關向新交所就建議第二上市提 交上市申請之公告（統稱「該等公告」）。除另有所 ...

Group 1 - The core viewpoint of the article is that Xiehe New Energy Group is progressing towards its international capital operations by filing for an overseas listing on the Singapore Stock Exchange through a backdoor listing method [1][2] - The company plans to utilize the introduction method for its listing, which does not require the issuance of new shares but allows for the cross-border transfer of existing shares, a common practice in mature overseas markets [1] - The China Securities Regulatory Commission (CSRC) has set clear requirements for information disclosure, mandating that the company report any significant events through the regulatory system until the completion of the overseas listing [1] Group 2 - The CSRC has established a 12-month validity period for the filing notice, requiring the company to update its filing materials and reapply if it does not complete the listing within this timeframe [2] - The listing is expected to enhance the company's international financing channels and brand influence, particularly in the green energy sector, as Singapore is a key financial hub in the Asia-Pacific region [2] - The market analysis indicates that this listing could attract more international long-term capital to support the company's global renewable energy business expansion [2]

保险资金凭借规模大、期限长、来源稳的显著优势，被视为天然的耐心资本，在服务国家战略、支 持实体经济和保障国计民生中，正发挥着日益关键的作用。 进入四季度以来，一场关于"险资引入"的竞速赛在全国多地拉开帷幕。从西部边疆到内陆腹地，多 地政府部门发布政策文件，将吸引保险资金作为激发区域经济活力、推动高质量发展的重要抓手，力求 通过政策"筑巢"，引来险资这只"金凤"。 地方政策频出推动"险资入地" 近期，地方政府及金融监管部门主动对接险资的力度不断加大，通过出台专项政策、搭建对接平 台、开展交流活动等多项举措，推动保险资金服务地方经济高质量发展。 例如，12月1日，西藏自治区人民政府印发《西藏自治区进一步激发经营主体活力推动投资促进高 质量发展的若干措施》，明确提出开展险资入藏（投藏）行动，探索与央企国企、大型民企合作，引导 长期耐心资本投资当地重点产业和项目。 11月26日，陕西省委金融办会同陕西省证监局、省科技厅、省工业和信息化厅、省国资委印发《关 于深化资本市场改革助力陕西高质量发展的若干措施》，明确提出"建立健全险资入陕机制，支持保险 资金参与设立私募创投基金"。政策发布后不久，随即举办的2025年陕西省" ...

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy as a first-line treatment for gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of a Phase III clinical trial for Nilotinib as a first-line treatment for Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharmaceutical-B (02595) initiated a registration clinical trial for GFH375, the world's first oral KRAS G12D inhibitor in a controlled chemotherapy Phase III study [1] - Xixiangfeng Group (02473) signed a business cooperation agreement with Hello Car Rental to develop car rental services in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for a GLP-1/GIP receptor dual agonist injection [1] - MIRXES-B (02629) plans to collaborate with Crystal Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automobile (01728) intends to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) plans to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) successfully included seven innovative products (including new indications) in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biotech-B (09887) presented clinical data for LBL-034 at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Acid Vovizili Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) successfully included five new products in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) had its core products included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported a contract sales amount of approximately 47.7 billion yuan for the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported an equity power generation of 697.23 GWh in November, a year-on-year increase of 7.77% [2]

Major Events - Chuangsheng Group-B (06628) announced updated efficacy data for osemitamab triple therapy in first-line treatment of gastric or gastroesophageal junction adenocarcinoma at ESMO Asia [1] - Strength Development (01277) plans to acquire 100% equity of Taiyuan Shidi for approximately 384 million yuan and acquire Dongzhimen property for a total of 86.33 million yuan [1] - Innovent Biologics (01801) completed a global strategic collaboration with Takeda Pharmaceutical and issued 6.9138 million shares under general authorization [1] - Ascentage Pharma-B (06855) received FDA and EMA approval for global registration of the III phase clinical study of Nilotinib in first-line treatment of Ph+ ALL [1] - Baiao Saitou-B (02315) announced that its business partner IDEAYA received IND approval from the FDA for IDE034 [1] - Jinfang Pharma-B (02595) initiated a registration clinical trial for GFH375 in metastatic pancreatic cancer, marking the first global oral KRAS G12D inhibitor monotherapy controlled chemotherapy III phase study [1] - Xixiangfeng Group (02473) subsidiary signed a business cooperation agreement with Hello Car Rental to develop car rental business in designated cities under a "co-branded store" model [1] - International Commercial Settlement (00147) signed a computer chip sales agreement with Hong Kong Antarctic Light to seize growth opportunities in the IC chip market [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval in the U.S. for GLP-1/GIP receptor dual agonist peptide injection [1] - MIRXES-B (02629) plans to collaborate with Jingtai Technology to build an AI-enabled integrated "diagnosis and treatment" research and industrialization platform [1] - Zhengtong Automotive (01728) plans to invest approximately 816 million yuan to acquire Xiamen Xinda 4S dealership and automotive sales and export business [1] - Guorui Life (00108) intends to acquire 78.3% of Beijing Chunyu Tianxia Software for 269 million yuan [1] - Innovent Biologics (01801) announced that seven innovative products, including new indications, were successfully included in the 2025 National Medical Insurance Drug List [1] - Peijia Medical-B (09996) had its registration application for the TaurusNXT® "non-aldehyde cross-linked" transcatheter aortic valve replacement system accepted by the National Medical Products Administration [1] - Fosun Pharma (02196) had new drugs included in the National Medical Insurance Directory and commercial insurance innovative drug directory [1] - Junshi Biosciences (01877) had Tuoyi® new indications and Junshida® included in the National Medical Insurance Directory [1] - Valiant Biopharma-B (09887) clinical data for LBL-034 was presented at the 67th ASH Annual Meeting [1] - Canfite BioPharma (09926) had all approved indications for five marketed drugs successfully included in the latest National Medical Insurance Drug List [1] - Fuhong Hanlin (02696) had Fuzhuoning® (Citrus Aurantium Extract Capsules) included in the National Medical Insurance Drug List [1] - Green Leaf Pharmaceutical (02186) had five new products successfully included in the 2025 National Medical Insurance Drug List or commercial insurance innovative drug directory [1] - Yinnuo Pharmaceutical-B (02591) core products were included in the National Medical Insurance Drug List [1] Operating Performance - Poly Real Estate Group (00119) reported contract sales of approximately 47.7 billion yuan in the first 11 months, a year-on-year decrease of 8.45% [2] - GAC Group (02238) reported November automobile sales of approximately 179,700 units, a year-on-year decline of 9.72% [2] - Xiehe New Energy (00182) reported November equity power generation of 697.23 GWh, a year-on-year increase of 7.77% [2]

Core Viewpoint - The company reported a year-on-year increase in equity power generation for November 2025, indicating positive growth in its operational performance [1] Group 1: Company Performance - The equity power generation for November 2025 reached 697.23 GWh, representing a 7.77% increase compared to the same month in the previous year [1] - The total equity power generation for the first eleven months of 2025 amounted to 7795.65 GWh [1]

协合新能源(00182)公布，该集团2025年11月权益发电量为697.23GWh，同比增长7.77%。前11个月权益 发电量为7795.65GWh。 ...